Last month the Department of Health and Social Care warned of a national shortage of certain drugs used to manage type 2 diabetes, known as GLP-1 receptor agonists.
These include the drugs liraglutide and semaglutide, which are licensed for diabetes management under the brand names Victoza and Ozempic respectively. There is also a shortage of liraglutide licensed for weight loss under the brand name Saxenda.
Supply is not expected to return to normal until at least mid-2024.
If you are you a medical professional or patient who has been affected by the shortage of these medications, please tell us about your situation.
